Novavax, Inc. (Nasdaq: NVAX), an American biotechnology company, announced on Friday that it has received expanded authorisation from Health Canada for its Nuvaxovid (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunisation to prevent COVID-19.
The vaccine will be a homologous booster in adults aged 18 and older.
Nuvaxovid has received expanded authorisation based on data from a phase two trials carried out in South Africa and from the Prevent-19 Phase three trial conducted in the United States and Mexico. Under the trials, a single booster dose of the product was administered to healthy adult participants around 6 to 11 months after their primary series of two doses administered three weeks apart. The third (booster) dose developed increased immune responses to levels comparable to or exceeding those associated with protection against COVID-19 in Phase three clinical trials.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma